RCM Eos PIPE Holdings

RCM Eos PIPE Holdings is a specialized investment vehicle formed to facilitate the financing of Eos Biosciences (now part of a merged entity with B. Riley Principal Merger Corp. II, eventually becoming Eos Therapeutics or related entities). The entity is primarily associated with the development of oncology therapeutics, specifically focusing on the clinical advancement of DHODH inhibitors. Its primary asset, subasumstat (formerly TAS-116 or similar derivatives in the Eos pipeline), is being evaluated for the treatment of hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndrome. The company operates as a financial bridge to support the clinical transition of high-potential biotech assets into the public markets.